Jason Bradley Terrell Md - Dec 8, 2021 Form 4 Insider Report for VOLITIONRX LTD (VNRX)

Role: Chief Medical Officer
Signature: /s/ Jason Terrell MD
Stock symbol: VNRX
Transactions as of: Dec 8, 2021
Transactions value $: $0
Form type: 4
Date filed: 12/10/2021, 03:05 PM
Previous filing: Nov 5, 2021
Next filing: Apr 8, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VNRX	Stock Option (Right to Buy)	Disposed to Issuer	-55K	-100%	0	Dec 8, 2021	Common Stock	55K	$3.60	Direct	F1
transaction	VNRX	Stock Option (Right to Buy)	Award	+55K		55K	Dec 8, 2021	Common Stock	55K	$3.60	Direct	F1
transaction	VNRX	Stock Option (Right to Buy)	Disposed to Issuer	-5K	-100%	0	Dec 8, 2021	Common Stock	5K	$3.60	By Spouse	F2
transaction	VNRX	Stock Option (Right to Buy)	Award	+5K		5K	Dec 8, 2021	Common Stock	5K	$3.60	By Spouse	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).
F2	The reported transactions involved an amendment of outstanding options granted to the reporting person's wife, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).

Content

The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).

The reported transactions involved an amendment of outstanding options granted to the reporting person's wife, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant).